Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate potential mechanisms of valproic acid-associated low serum albumin in medically fragile pediatric and young adult epileptic patients of a long-term care facility.

Clinical Trial Description

Valproic acid (VPA) is a long-chain fatty acid frequently used as an antiepileptic agent in pediatric and adult seizure patients. Other adverse effects that have been associated with VPA use include hepatic steatosis, altered mitochondrial function and decreased concentrations of serum proteins. The exact mechanism or mechanisms by which VPA induces these associated adverse drug effects are not fully understood though multiple theories have been postulated including impaired vesicle transport within the hepatocyte, inhibition of hepatic synthetic metabolic pathways and renal protein loss. Decreased serum albumin concentrations with concomitant VPA use have been identified in multiple studies. Albumin synthesis is sensitive to tryptophan concentrations (other amino acids are also able to stimulate albumin synthesis), oncotic pressure near the synthetic site, and energy supply while albumin release from the hepatocyte is sensitive to intrahepatocellular potassium concentrations. Based on available literature, VPA appears to inhibit an enzyme(s) either directly or indirectly involved with albumin synthesis or albumin gene expression. VPA is known to inhibit the urea cycle, including patients with ornithine-transcarbamylase (OTC) deficiency, possibly by inhibiting mitochondrial carbamoyl-phosphate synthase. Oratz et al discussed the potential correlation between the urea cycle and albumin synthesis identified after the administration of various amino acids increased both albumin and urea synthesis. Ornithine is an intermediate amino acid within the urea cycle and it is also a precursor to polyamines which have been shown to increase the degree of aggregation of polysomes, responsible for protein synthesis, bound to the endoplasmic reticulum. Thus, VPA may indirectly inhibit protein synthesis by interfering with the urea cycle leading to decreased ornithine concentrations and subsequently a decrease in polyamine concentrations and a decrease in the number of bound polysomes resulting in alterations in albumin synthesis and release. The purpose of this study is to investigate potential mechanisms of VPA-associated hypoalbuminemia in medically fragile pediatric and young adult epileptic patients of a long-term care facility. ;

Study Design

Observational Model: Case Control

Related Conditions & MeSH terms

Hypoalbuminemia

Clinical Trial Details

NCT number	NCT00723762
Study type	Observational
Source	Akron Children's Hospital
Contact
Status	Completed
Phase	N/A
Start date	February 2009
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05050851` - Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
Terminated	`NCT00529633` - The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients	Phase 3
Active, not recruiting	`NCT03675906` - The Relationship Between Hypoalbuminemia and Development of Acute Kidney Failure (AKI) According to KDIGO Criteria
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03569410` - The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients	N/A
Terminated	`NCT02457702` - Mitochondrial Function in Patients With Severe Liver Disease	N/A
Active, not recruiting	`NCT02288494` - Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach	N/A
Completed	`NCT02765061` - Hyponatremia and Hypoalbuminemia is Morbimortality Predictors in Coronary Artery Bypass Graft Surgery	N/A
Completed	`NCT03167645` - SUbstition of PERioperative Albumin Deficiency Disorders	Phase 4
Recruiting	`NCT05797649` - Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis
Completed	`NCT01822600` - The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia	Phase 4
Completed	`NCT01542749` - Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer	N/A
Completed	`NCT00561093` - Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients	Phase 3
Completed	`NCT04046263` - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients	Phase 4
Completed	`NCT00597025` - Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin	N/A
Completed	`NCT06355479` - A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.